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Long-term responseAbstract Background: The addition of palbociclib to fulvestrant improved clinical outcomes
over placebo-fulvestrant in endocrine-pretreated metastatic breast cancer (MBC) patients in
PALOMA-3. Here, we examined factors predictive of long-term benefit.
Methods: Premenopausal-peri/postmenopausal patients with endocrine-resistant, hormone re-
ceptorepositive (HRþ)/human epidermal growth factor receptor 2enegative MBC were ran-
domised 2:1 to fulvestrant (500 mg) and either palbociclib (125 mg/d; 3/1 schedule; nZ 347) or
placebo (n Z 174). Baseline characteristics, mutation status and HR expression levels were
compared in patients with and without prolonged benefit (treatment duration 18 months).
Results: By August 2016, 100 patients (29%) on palbociclib-fulvestrant and 26 (15%) on
placebo-fulvestrant demonstrated prolonged benefit, with long-term responders in both arms
sharing common clinical characteristics. They usually had less disease burden at baseline
versus those treated <18 months, such as having one disease site (40% vs 29% on
palbociclib-fulvestrant and 69% vs 29% on placebo-fulvestrant), bone-only disease (32% vs
22% and 46% vs 17%) and were less heavily pretreated (69% vs 56% and 73% vs 60% had
2 prior therapies). Baseline tumour ESR1 and PIK3CA mutation rates were lower among
long-term responders in both arms; median oestrogen receptor H-scores were similar, whereas
progesterone receptor H-scores were higher among long-term responders.
Conclusions: This exploratory analysis demonstrates that some patients with endocrine-
resistant MBC derive significant and prolonged benefit when treated with palbociclib-
fulvestrant, with fewer patients experiencing similar efficacy with placebo-fulvestrant. The cur-
rent analysis did not identify specific molecular or clinical factors prognostic of long-term
benefit with palbociclib-fulvestrant (ClinicalTrials.gov, NCT01942135).
ª 2018 The Authors and Pfizer Inc. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Endocrine therapy (ET) remains the current standard
treatment for hormone receptorepositive (HRþ),
human epidermal growth factor receptor 2enegative
(HER2e) breast cancer [1,2]. Although some patients
have a prolonged clinical response to ET alone, many
fail to benefit from ET alone or develop resistant disease
[3,4]. Considerable effort has been made to improve the
efficacy of endocrine-based therapies to delay the use of
chemotherapy and optimise both the length and quality
of life of patients [1].
Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/
6) enhance ET activity and significantly improve clinical
outcomes in patients with breast cancer [5e9]. Palbociclib
(IBRANCE) is a first-in-class, orally bioavailable inhib-
itor of CDK4/6 approved for the treatment of HRþ/
HER2 metastatic breast cancer (MBC) in combination
with fulvestrant in pre/perimenopausal and post-
menopausal women with disease progression after ET and
in combination with an aromatase inhibitor as initial
endocrine-based therapy in postmenopausal women [10].
In the phase 3, randomised, double-blind PALOMA-3
study, palbociclib plus fulvestrant demonstrated signifi-
cantly improved efficacy versus placebo plus fulvestrant in
patients with endocrine-resistant HRþ/HER2 MBC,
withmedian progression-free survival (PFS) of 11.2 versus
4.6 months, respectively (hazard ratio [HR], 0.50; 95%
confidence interval [CI], 0.40e0.62; one-sided P< 0.0001)
[11,12]. Although ET is more effective overall when com-
bined with a CDK4/6 inhibitor [13e16], prolongedresponses have been observed in subsets of patients with
breast cancer receiving ET alone [17]. Therefore, the
identification of clinical or molecular markers that predict
which patients may derive the largest benefit from mono-
therapy versus a combination is vitally important to
inform clinical decisions and could significantly improve
themanagement of breast cancer.We, therefore, evaluated
baseline characteristics of patients with HRþ/HER2e
MBC as predictors of prolonged benefit with palbociclib-
fulvestrant or placebo-fulvestrant.
2. Methods
2.1. Patients
Eligible patients were women aged 18 years of any
menopausal status with HRþ/HER2e MBC whose
disease had progressed on prior ET (i.e. aromatase in-
hibitors for postmenopausal women and tamoxifen for
premenopausal women). Patients were allowed one
prior line of chemotherapy in the advanced setting;
those who received prior treatment with any CDK in-
hibitor, fulvestrant, everolimus or any phosphoinositide
3-kinase or mammalian target of rapamycin pathway
inhibitor were excluded. Full eligibility criteria are re-
ported elsewhere [5,7].
2.2. Study design
The design of the PALOMA-3 study (NCT01942135)
was described previously [5,7]. Briefly, patients in this
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intramuscularly) and either palbociclib (125 mg/d orally
for 3 weeks followed by 1 week off) or matching
placebo. Premenopausal/perimenopausal women were
required to receive luteinising hormoneereleasing hor-
mone agonist 4 weeks before study treatment and
agree to switch to goserelin at randomisation. Ran-
domisation was stratified by the presence of visceral
metastasis, menopausal status at study entry (post
vs pre/peri) and sensitivity to prior ET. Treatment
continued until disease progression, unacceptable toxi-
city or study withdrawal. The study was conducted in
accordance with the Declaration of Helsinki. The pro-
tocol was approved by an institutional review board, or
equivalent, for each site, and all patients provided
informed consent before enrolment.
Baseline plasma samples were collected for circu-
lating tumour DNA analysis and processed within 1 h as
described previously [5]. BEAMing assays were used to
detect mutations (Sysmex Inostics; Baltimore, MD,
USA). ESR1-positive mutation status was defined as
0.1% for any nucleotide change; PIK3CA-positive
mutation status was defined as 0.02%. H-scores were
calculated as the sum of the percentage of cells at each
level of the staining intensity multiplied by the staining
intensity value; values could range from 0 to 300.
2.3. End-points
The primary end-point of PALOMA-3 was investigator-
assessed PFS according to Response Evaluation Criteria
in Solid Tumors v1.1 criteria. Secondary end-points
included objective response (clinical response is reported
as a radiologically confirmed response), clinical benefit
response (defined as complete response, partial res-
ponse or stable disease for 24 weeks), overall survival
(OS) and safety. Tumour assessments were performed at
baseline and every 8 weeks for the first year and every 12
weeks thereafter.
2.4. Statistical analysis
The long-term benefit patients were identified using the
August 31, 2016, data set that collected demographics,
baseline characteristics, exposure, time on treatment and
safety data only. Long-term benefit was defined as
treatment duration 18 months (without disease pro-
gression) by August 31, 2016; results by treatment
duration 12 and < 12 months are also reported based
on the August 31, 2016, data set. In addition, the most
recent efficacy data cut-off of October 23, 2015, was
used to evaluate the primary end-point (PFS) for these
long-term benefit patients, which was the last efficacy
data collection time point. Subgroup analyses of PFS
were exploratory. The KaplaneMeier method was used
to estimate median PFS, and the two-sided log-rank testwas used for comparisons of PFS. HRs and two-sided
95% CIs were estimated using the Cox proportional
hazards model. Expression of oestrogen receptor (ER)
and progesterone receptor (PR) was evaluated at a
central laboratory by validated immunohistochemistry,
and results were quantified using H-score methodology.
Unless otherwise noted for efficacy data, all data were
obtained from the August 31, 2016, cut-off.
3. Results
3.1. Patients and treatment exposure
Between September 26, 2013, and August 26, 2014, 521
patients from 144 centres in 17 countries were randomised
to palbociclib-fulvestrant (nZ 347) or placebo-fulvestrant
(n Z 174) in the PALOMA-3 study (Fig. A1). As of
August 31, 2016, 100 (29%) of the 347 patients randomised
to palbociclib-fulvestrant received treatment for 18
months, including 70 (20%) who received treatment for>2
years (26e39 cycles). In contrast, 26 (15%) of 174 patients
in the placebo-fulvestrant arm received 18 months of
treatment, and only 16 patients (9%) were treated for >2
years (27e38 cycles). Similarly, a greater proportion of
patients in the palbociclib-fulvestrant versus control arm
received12months of treatment (154 [44%] vs 38 [22%]).
The mean overall time on treatment was 12.5 (standard
deviation [SD], 9.3) months in the palbociclib-fulvestrant
arm and 7.9 (8.1) months in the placebo-fulvestrant arm
(Table A1). Mean (SD) duration of treatment among pa-
tients with prolonged benefit on palbociclib-fulvestrant
was 25.2 (3.2) months versus 7.4 (5.1) months for those
with <18 months of treatment. The mean (SD) of treat-
ment among long-term responders in the control group
was 24.6 (3.5) months versus 4.9 (4.1) months for patients
with <18 months of treatment.
Patient demographics and baseline characteristics are
shown in Table 1 and Table A2. In both arms, patients
with long-term benefit tended to have less disease
burden at baseline than those treated for shorter dura-
tions. Among patients treated with palbociclib-
fulvestrant, 40% of those with prolonged benefit had a
single site of disease involvement and 32% had bone-
only disease compared with 29% and 22%, respec-
tively, of those treated for <18 months. Among patients
treated with placebo-fulvestrant, 69% of long-term re-
sponders had a single site of disease involvement and
46% had bone-only disease compared with 29% and
17%, respectively, of those treated for <18 months.
Patients with prolonged benefit versus those treated for
<18 months also typically had an earlier line of therapy
(69% vs 56% in the palbociclib-fulvestrant arm and 73%
vs 60% in the placebo-fulvestrant arm had received 2
prior therapies) and were sensitive to prior hormonal
therapy (86% vs 76% in the palbociclib-fulvestrant arm
and 81% vs 75% in the placebo-fulvestrant arm).
Table 1
Patient demographics and baseline characteristics.
Characteristics 18 months <18 months
Palbociclib-fulvestrant
(n Z 100)
Placebo-fulvestrant
(n Z 26)
Palbociclib-fulvestrant
(n Z 245)
Placebo-fulvestrant
(n Z 146)
Age, years
Median (range) 59 (34e82) 61 (35e79) 56 (30e88) 55 (29e80)
65 33 (33) 5 (19) 53 (22) 38 (26)
Race
White 72 (72) 21 (81) 179 (73) 110 (75)
Asian 23 (23) 4 (15) 50 (20) 27 (19)
Black and other 5 (5) 1 (4) 15 (6) 8 (5)
ECOG performance status
0 61 (61) 20 (77) 143 (58) 94 (64)
1 39 (39) 6 (23) 102 (42) 52 (36)
Menopausal status
Premenopausal/perimenopausal 23 (23) 5 (19) 48 (20) 31 (21)
Postmenopausal 77 (77) 21 (81) 197 (80) 115 (79)
Sensitive to prior hormonal therapy 86 (86) 21 (81) 186 (76) 110 (75)
Visceral metastases 44 (44) 8 (31) 155 (63) 96 (66)
Bone-only disease 32 (32) 12 (46) 53 (22) 25 (17)
Measurable disease 69 (69) 15 (58) 197 (80) 122 (84)
Disease stage at initial diagnosis
I 4 (4) 1 (4) 21 (9) 11 (8)
II 37 (37) 12 (46) 82 (33) 44 (30)
III 17 (17) 8 (31) 52 (21) 39 (27)
IV 29 (29) 3 (12) 57 (23) 32 (22)
Other/missing 5 (5) 2 (8) 8 (3) 6 (4)
Recurrence type
Local/locoregional 10 (10) 3 (12) 24 (10) 15 (10)
Regional 2 (2) 1 (4) 13 (5) 6 (4)
Distant 68 (68) 21 (81) 159 (65) 98 (67)
Newly diagnosed 20 (20) 0 47 (19) 25 (17)
Disease-free interval, months
<12 2 (2) 0 9 (4) 3 (2)
12e24 3 (3) 2 (8) 26 (11) 17 (12)
>24 59 (59) 18 (69) 131 (54) 82 (56)
Disease site
Bone 81 (81) 20 (77) 183 (75) 109 (75)
Breast 21 (21) 1 (4) 39 (16) 17 (12)
Liver 18 (18) 4 (15) 109 (45) 77 (53)
Lung 26 (26) 4 (15) 74 (30) 40 (27)
Lymph node 31 (31) 6 (23) 107 (44) 57 (39)
Other 32 (32) 4 (15) 90 (37) 47 (32)
Disease sites, n
1 40 (40) 18 (69) 71 (29) 42 (29)
2 33 (33) 4 (15) 62 (25) 46 (32)
3 9 (9) 3 (12) 64 (26) 30 (21)
4 14 (14) 1 (4) 32 (13) 19 (13)
5 4 (4) 0 16 (7) 9 (6)
Prior surgeries 75 (75) 23 (89) 208 (85) 123 (84)
Prior radiation therapy 63 (63) 21 (81) 172 (70) 109 (75)
Prior chemotherapy
Neoadjuvant 17 (17) 1 (4) 49 (20) 31 (21)
Adjuvant 44 (44) 18 (69) 106 (43) 70 (48)
Advanced/metastatic 26 (26) 6 (23) 78 (32) 54 (37)
Tamoxifen only 3 (3) 0 2 (<1) 4 (3)
Aromatase inhibitors only 17 (17) 2 (8) 29 (12) 14 (10)
Tamoxifen and aromatase inhibitors 38 (38) 10 (39) 120 (49) 70 (48)
Prior therapies, n
1 29 (29) 8 (31) 53 (22) 34 (23)
2 40 (40) 11 (42) 85 (35) 54 (37)
3 16 (16) 3 (12) 68 (28) 36 (25)
4 15 (15) 4 (15) 39 (16) 22 (15)
ECOG, Eastern Cooperative Oncology Group.
Data are n (%) unless noted otherwise.
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measurable disease at baseline than patients treated for
<18 months (69% vs 80% in the palbociclib-fulvestrant
arm and 58% vs 84% in the placebo-fulvestrant arm).
In the palbociclib-fulvestrant arm, fewer patients with
prolonged benefit had prior surgeries at baseline com-
pared with those treated for <18 months (75% vs 85%).
Among patients receiving palbociclib-fulvestrant, the
type of disease recurrence did not appear to affect the
duration of benefit (Table 1 and Table A2). However, in
the placebo-fulvestrant arm, none of the 25 patients
newly diagnosed with metastatic disease received 12
months of treatment.
3.2. Efficacy
After a median follow-up of 14.0 months (95% CI,
13.9e14.5) in the palbociclib-fulvestrant group, in the
intent-to-treat (ITT) population, median PFS was 11.2
months (95% CI, 9.5e12.9), which was more than
double that of the placebo-fulvestrant group (4.6
months [95% CI, 3.5e5.6]) (HR, 0.497; 95% CI, 0.398e
0.620; 1-sided P < 0.0001; Fig. 1A). Median PFS was
significantly improved with the addition of palbociclib
in patients with bone-only metastases (Fig. 1B), in pa-
tients with only one prior therapy (Fig. 1C), in patients
with 2 disease sites (Fig. 1D) and in patients with prior
sensitivity to hormonal therapy (Fig. 1E; all P < 0.05).
Compared with the placebo-fulvestrant group, median
PFS also improved significantly with the addition of
palbociclib in patients without bone-only metastases
(Fig. 2A), in patients with >1 prior therapy
(Fig. 2B) and in patients with 3 disease sites (Fig. 2C;
all P < 0.0005); improvements with palbociclib-
fulvestrant versus placebo-fulvestrant in patients with
no prior sensitivity to hormonal therapy were not sig-
nificant (Fig. 2D). In the ITT population and in each
of the subgroups analysed, the PFS benefit with
palbociclib-fulvestrant was also observed in patients
with 12 months and 18 months of treatment.
3.3. Baseline ESR1 and PIK3CA analysis
A total of 395 patients had baseline circulating free
DNA evaluable for mutation analysis. Mutations in
ESR1 and PIK3CA have been implicated as mechanisms
for endocrine resistance in MBC [18]. In both arms, the
incidences of baseline ESR1 and PIK3CA mutations
were lower among patients treated for 18 months
versus those treated for <18 months; however, the dif-
ference was more pronounced among patients treated
with placebo-fulvestrant (Table 2). In the palbociclib-
fulvestrant group, 19% of long-term responders versus
28% of patients treated for <18 months had ESR1
mutations and 24% versus 37% had PIK3CA mutations
at baseline, respectively. In comparison, 6% of patients
with prolonged benefit on placebo-fulvestrant versus33% of those treated for <18 months had ESR1 muta-
tions and 6% versus 39% had PIK3CA mutations,
respectively (Table 2).3.4. Baseline hormone receptor expression
Most patients with long-term benefit had a valid baseline
assessment of ER and PR status. In the palbociclib-
fulvestrant arm, 70% of long-term responders had a valid
ER assessment at baseline and 69% had a valid PR
assessment. Among patients treated with placebo-
fulvestrant, 88% of those treated for 18 months had a
valid baseline ER and PR assessment. As shown in Table
2, mean (SD) ER H-scores were similar among long-term
responders and those treated for <18 months in both the
palbociclib-fulvestrant arm (125 [73] and 100 [74],
respectively) and the placebo-fulvestrant arm (101 [68]
and 99 [74], respectively); similar results were observed in
patients with and without 12 months of treatment. In
contrast, mean (SD) PR H-scores were higher among
long-term responders than those treated for <18 months
with both palbociclib-fulvestrant (72 [76] vs 45 [63]) and
placebo-fulvestrant (82 [74] vs 46 [58]). Median ER H-
scores were similar among patients with and without
prolonged benefit and were similar between treatment
groups (Table 2). Median PR H-scores were higher
among long-term responders, regardless of the treatment
group, and were lower overall among patients in the
palbociclib-fulvestrant versus the placebo-fulvestrant
group.4. Discussion
PALOMA-3 was a prospective, randomised, multi-
centre, placebo-controlled study evaluating palbociclib
plus fulvestrant versus placebo plus fulvestrant in pa-
tients with HRþ/HER2e MBC that had progressed on
prior ET [7]. The study demonstrated improved PFS
and objective response rates at predetermined time
points with the combination; subgroup analyses have
shown that the observed benefit was independent of
menopausal status, previous ET, number of disease
sites, previous lines of ET, sensitivity to previous hor-
monal therapy, previous chemotherapy [5,7] and pres-
ence of visceral metastases at baseline [19]. Furthermore,
patients receiving the combined regimen experienced an
improvement in the quality of life and a favourable
toxicity profile [20e22]. However, a detailed retrospec-
tive biomarker analysis was unable to identify factors
prognostic of response or benefit [5].
To identify potential predictors of prolonged benefit
with palbociclib-fulvestrant, this exploratory analysis
evaluated clinical and biological characteristics of the
subset of patients with long-term benefit on the combi-
nation. No specific molecular or clinical factors prog-
nostic of long-term benefit with palbociclib-fulvestrant
(A)
(B)
(C)
Fig. 1. Progression-free survival in the ITT population (A), in patients with bone-only metastases (B), with one prior therapy (C), one or
two disease sites (D) and sensitivity to prior hormonal therapy (E). FUL, fulvestrant; HR, hazard ratio; ITT, intent-to-treat; NE, not
estimable; PAL, palbociclib; PBO, placebo; PFS, progression-free survival; CI, confidence interval.
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(D)
(E)
Fig. 1. (continued).
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mutation status did not preclude patients from obtaining
prolonged benefit from the combination. With extended
follow-up, we continued to observe a remarkable dif-
ference in disease control and prolonged therapeutic
benefit with the combination. Approximately one-third
of patients who received palbociclib-fulvestrant had
derived prolonged benefit from the combination and
continued to receive treatment for a median of >2 years.
Among patients receiving palbociclib-fulvestrant, 29%
were without disease progression 18 months after
enrolment compared with only 15% in the fulvestrant
arm. Although substantially fewer patients achieved
long-term benefit with placebo-fulvestrant, these patients
did as well as patients who achieved long-term benefit
with palbociclib-fulvestrant, as suggested by the similar
mean durations of therapy. The data indicate that pal-
bociclib can maintain ET benefit for a relatively long
time in patients with HRþ MBC that progressed on
prior ET and can reduce endocrine resistance in combi-
nation with ET.The comparison between patients with and without
prolonged benefit showed that there were no major
differences in certain clinical characteristics, such as the
menopausal status and type of prior ET. Nevertheless,
patients achieving long-term benefit were more likely to
have a lower disease burden at baseline; they tended to
have fewer disease sites, non-visceral disease as indi-
cated by a lower incidence of liver metastases, a higher
incidence of bone-only disease and were less heavily
pretreated. Furthermore, the efficacy of the combina-
tion regimen was superior to single-agent treatment
across subsets of patients, including those with char-
acteristics considered favourable for ET. Interestingly,
the biomarker analysis showed that the baseline ER
expression level had no impact on treatment duration,
whereas the baseline PR expression level was higher
among long-term responders in both arms. The fre-
quencies of baseline ESR1 and PIK3CA mutations were
lower in patients with extended benefit, particularly in
those treated with placebo-fulvestrant. Although the
data are exploratory, not conclusive and cannot drive
(A)
(B)
Fig. 2. Progression-free survival in patients without bone-only metastases (A), with >1 prior therapy (B), 3 disease sites (C) and no prior
sensitivity to hormonal therapy (D). FUL, fulvestrant; HR, hazard ratio; PAL, palbociclib; PBO, placebo; PFS, progression-free survival;
CI, confidence interval.
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in understanding and continuing to explore the prog-
nostic role of molecular diagnostics and the disease site.
It is also relevant to consider the impact of other ther-
apeutic options on this specific setting to better under-
stand the effect of the combination.
BOLERO-2 was a multicentre, double-blind, rando-
mised, placebo-controlled, phase 3 study comparing
exemestane plus everolimus with single-agent exemes-
tane in patients with MBC [23]. The clinical character-
istics of patients in this study were similar to those of
patients in PALOMA-3. Patients enrolled in BOLERO-
2 had previously received systemic therapy for meta-
static disease, most commonly ET (primarily an aro-
matase inhibitor), but patients exposed to chemotherapy
were also included [23]. Similar to PALOMA-3, the
combination regimen demonstrated superior efficacy
with improved PFS; however, no impact on OS was
observed at the final planned PFS analysis, and after amedian follow-up of 18 months, only 16.7% of patients
were still receiving the planned study treatment [24,25].
Furthermore, patients treated with everolimus experi-
enced significant treatment-related toxicity, with 55% of
patients reporting grade III/IV toxicity, resulting in a
median time of exposure to the everolimus combination
of 23.9 weeks for the overall study group [24]. Consid-
ering the toxicity reported with everolimus, palbociclib-
fulvestrant represents a highly appropriate and well-
tolerated choice [26,27].
An alternative treatment option for this population is
chemotherapy, primarily single-agent treatment with
drugs such as capecitabine, eribulin and a taxane [28].
Treatment with these agents is typically associated with
significant toxicity other than neutropenia (an adverse
event commonly associated with palbociclib) and, in
many cases, requires dose reductions and/or treatment
discontinuation, primarily because of the onset of long-
term, non-haematologic toxicity. Furthermore, some of
(C)
(D)
Fig. 2. (continued).
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substantial impact on costs and patient’s quality of life.
However, the current costs of targeted therapies such as
palbociclib are higher than those of chemotherapy [29],
and no head-to-head studies have been conducted toTable 2
Baseline mutation rate and hormone receptor expression.
Palbociclib-fulvestrant
18 months <18 months 12 months <1
Mutation
ESR1, n/N (%) 15/80 (19) 52/185 (28) 25/120 (21) 42
PIK3CA, n/N (%) 19/80 (24) 68/185 (37) 31/120 (26) 56
Median (range) H-score
Oestrogen receptor 130 (0e250) 100 (0e280) 120 (0e250) 10
Progesterone receptor 40 (0e270) 6 (0e240) 30 (0e270) 6 (
Mean (SD) H-score
Oestrogen receptor 125 (73) 100 (74) 118 (72) 98
Progesterone receptor 72 (76) 45 (63) 62 (72) 46
SD, standard deviation.
ESR1-positive mutation status was defined as 0.1% for any nucleotide ch
H-score was calculated as the sum of the percentage of cells at each level of
range from 0 to 300.directly compare the efficacy, tolerability, quality of
life or treatment compliance between chemotherapy and
palbociclib combination therapy. Nevertheless, our
analysis showed that, in a subset of patients who only
had one line of prior therapy, including patients whoPlacebo-fulvestrant
2 months 18 months <18 months 12 months <12 months
/145 (29) 1/16 (6) 38/115 (33) 4/27 (15) 35/104 (34)
/145 (39) 1/16 (6) 45/115 (39) 9/27 (33) 37/104 (36)
0 (0e280) 120 (0e260) 117 (0e180) 115 (0e260) 119 (0e280)
0e240) 70 (0e230) 10 (0e230) 50 (0e230) 10 (0e230)
(75) 101 (68) 99 (74) 94 (70) 101 (74)
(65) 82 (74) 46 (58) 66 (69) 48 (60)
ange; PIK3CA-positive mutation status was defined as 0.02%.
the staining intensity multiplied by the staining intensity value; values
M. Cristofanilli et al. / European Journal of Cancer 104 (2018) 21e3130may have received chemotherapy in the MBC setting,
median PFS was prolonged with the combination.
This analysis was exploratory in nature with limited
statistical methods performed. Additionally, this analysis
was limited by the small number of patients included
overall and especially in the ESR1 and PIK3CA analyses
because evaluable baseline circulating free DNA samples
were not available from all patients. Nevertheless, find-
ings from this analysis provide novel clinical insights into
the subset of patients with long-term benefit from pal-
bociclib-fulvestrant.
In summary, this extended analysis of palbociclib
plus fulvestrant in the context of the PALOMA-3 study
indicates the possibility of significant long-term benefit
for patients with HRþ/HER2e MBC after failure of
previous ET. Although no new biomarkers were iden-
tified for predicting long-term benefit other than those
identified in previous studies (namely, low disease
burden and limited treatment for advanced disease), it is
possible that increased genomic variants associated with
aggressive endocrine-resistant disease could aid future
treatment selection, with potential implications for use
of other therapies, including immune therapy [30].Conflict of interest statement
Massimo Cristofanilli has been a consultant or on
the advisory board for Dompe´ Farmaceutici, Cynvenio
Biosystems, Newomics and Vortex Biosciences and
received honoraria from Pfizer, Celgene, Dompe´
Farmaceutici and Agendia. Angela DeMichele has
received honoraria from Pfizer, and her institution
received research funding from Genentech, Pfizer,
Incyte, Millennium, Bayer, Veridex, Calithera Bio-
sciences, GlaxoSmithKline and Wyeth. Nicholas Turner
has received honoraria from and been a consultant or
on the advisory board for Pfizer, and his institution has
received research funding from Servier, Pfizer, Eli Lilly,
Roche and AstraZeneca. Dennis Slamon has served in a
leadership position for BioMarin and has stock or other
ownership interests in Pfizer. Seock-Ah Im has been a
consultant or on the advisory board for AstraZeneca,
Novartis, Roche and Spectrum and has received
research funding from AstraZeneca. Norikazu Masuda
has received honoraria from Chugai, AstraZeneca and
Kyowa-Kirin, and his institution received research
funding from Chugai, Pfizer, Novartis, Lilly, Astra-
Zeneca and Kyowa-Kirin. Shailendra Verma has been a
consultant or on the advisory board for Pfizer. Sherene
Loi’s institution has received research funding from
Roche/Genentech, Pfizer, Novartis, Merck, Puma
Biotechnology and Bristol-Myers Squibb. Marco Col-
leoni has been a consultant or on the advisory board for
Pierre Fabre, Pfizer, OBI Pharma, Puma Biotechnology,
Celldex and AstraZeneca and received honoraria from
Novartis. Kathy Puyana Theall, Xin Huang, Yuan Liuand Cynthia Huang Bartlett are employees of and own
stock in Pfizer. Carla Giorgetti was an employee of
Pfizer when the manuscript was initiated.
Author contributions
Massimo Cristofanilli, Nicholas Turner, Dennis Sla-
mon, Seock-Ah Im, Norikazu Masuda and Cynthia
Huang Bartlett contributed to study concepts and study
design. Massimo Cristofanilli, Angela DeMichele,
Nicholas Turner, Dennis Slamon, Seock-Ah Im, Nor-
ikazu Masuda, Shailendra Verma, Sherene Loi and
Marco Colleoni helped in data acquisition. Carla
Giorgetti, Kathy Puyana Theall, Xin Huang, Yuan Liu
and Cynthia Huang Bartlett were involved in quality
control of data and algorithms. Xin Huang helped in
statistical analysis. All authors were involved in the
preparation, editing and reviewing of the manuscript
and in data analysis and interpretation.
Funding
This study was funded by Pfizer Inc.
Acknowledgements
This study was sponsored by Pfizer Inc, USA.
Editorial support was provided by Johna Van Stelten,
PhD, and Anny Wu, PharmD, of Complete Healthcare
Communications, LLC (North Wales, PA), a CHC
Group Company.
Appendix A. Supplementary data
Supplementary data related to this article can be found
at https://doi.org/10.1016/j.ejca.2018.08.011.
References
[1] Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd interna-
tional consensus guidelines for Advanced Breast Cancer (ABC2).
Ann Oncol 2014;25:1871e88. https://doi.org/10.1093/annonc/
mdu385.
[2] National Comprehensive Cancer Network. NCCN clinical prac-
tice guidelines in oncology (NCCN Guidelines). Breast Cancer
2017. Version 4. Available at: https://www.nccn.org/professionals/
physician_gls/pdf/breast.pdf. [Accessed 12 February 2018].
[3] Hayes EL, Lewis-Wambi JS. Mechanisms of endocrine resistance
in breast cancer: an overview of the proposed roles of noncoding
RNA. Breast Cancer Res 2015;17:40. https://doi.org/10.1186/
s13058-015-0542-y.
[4] Turner NC, Neven P, Loibl S, Andre F. Advances in the treat-
ment of advanced oestrogen-receptor-positive breast cancer.
Lancet 2017;389:2403e14. https://doi.org/10.1016/s0140-6736(16)
32419-9.
[5] Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus
palbociclib versus fulvestrant plus placebo for treatment of
hormone-receptor-positive, HER2-negative metastatic breast
cancer that progressed on previous endocrine therapy (PALOMA-
M. Cristofanilli et al. / European Journal of Cancer 104 (2018) 21e31 313): final analysis of the multicentre, double-blind, phase 3 rando-
mised controlled trial. Lancet Oncol 2016;17:425e39. https:
//doi.org/10.1016/S1470-2045(15)00613-0.
[6] Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6
inhibitor palbociclib in combination with letrozole versus letro-
zole alone as first-line treatment of oestrogen receptor-positive,
HER2-negative, advanced breast cancer (PALOMA-1/TRIO-
18): a randomised phase 2 study. Lancet Oncol 2015;16:25e35.
https://doi.org/10.1016/S1470-2045(14)71159-3.
[7] Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-
receptor-positive advanced breast cancer. N Engl J Med 2015;
373:209e19. https://doi.org/10.1056/NEJMoa1505270.
[8] Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as
first-line therapy forHR-positive, advanced breast cancer.NEngl J
Med 2016;375:1738e48. https://doi.org/10.1056/NEJMoa1609709.
[9] Sledge Jr GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib
in combination with fulvestrant in women with HRþ/HER2-
advanced breast cancer who had progressed while receiving
endocrine therapy. J Clin Oncol 2017;35:2875e84. https:
//doi.org/10.1200/jco.2017.73.7585.
[10] Ibrance (palbociclib). Full prescribing information. New York,
NY: Pfizer; 2018. http://labeling.pfizer.com/ShowLabeling.aspx?
idZ2191.
[11] Kim ES, Scott LJ. Palbociclib: a review in HR-positive, HER2-
negative, advanced or metastatic breast cancer. Target Oncol
2017;12:373e83. https://doi.org/10.1007/s11523-017-0492-7.
[12] European Medicines Agency. Ibrance hard capsules: summary of
product characteristics. July 25, 2017. http://www.ema.europa.eu/
docs/en_GB/document_library/EPAR_-_Product_Information/
human/003853/WC500217196.pdf.
[13] Chirila C, Mitra D, Colosia A, et al. Comparison of palbociclib in
combination with letrozole or fulvestrant with endocrine therapies
for advanced/metastatic breast cancer: network meta-analysis.
Curr Med Res Opin 2017:1e25. https://doi.org/10.1080/03007995.
2017.1325730.
[14] Kwapisz D. Cyclin-dependent kinase 4/6 inhibitors in breast
cancer: palbociclib, ribociclib, and abemaciclib. Breast Cancer
Res Treat 2017;166:41e54. https://doi.org/10.1007/s10549-017-
4385-3.
[15] Spring L, Bardia A, Modi S. Targeting the cyclin D-cyclin-
dependent kinase (CDK) 4/6-retinoblastoma pathway with selec-
tive CDK 4/6 inhibitors in hormone receptor-positive breast
cancer: rationale, current status, and future directions. Discov
Med 2016;21:65e74. https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC5477652/pdf/nihms865194.pdf.
[16] Shah AN, Cristofanilli M. The growing role of CDK4/6 inhibitors
in treating hormone receptor-positive advanced breast cancer.
Curr Treat Options Oncol 2017;18:6. https://doi.org/10.1007/
s11864-017-0443-7.
[17] Boer K. Fulvestrant in advanced breast cancer: evidence to date
and place in therapy. Therapeut Adv Med Oncol 2017;9:465e79.
https://doi.org/10.1177/1758834017711097.
[18] Lefebvre C, Bachelot T, Filleron T, et al. Mutational profile of
metastatic breast cancers: a retrospective analysis. PLoS Med
2016;13, e1002201. https://doi.org/10.1371/journal.pmed.1002201.[19] Turner NC, Finn RS, Martin M, et al. Clinical considerations of
the role of palbociclib in the management of advanced breast
cancer patients with and without visceral metastases. Ann Oncol
2018;29:669e80. https://doi.org/10.1093/annonc/mdx797.
[20] Loibl S, Turner NC, Ro J, et al. Palbociclib combined with fulves-
trant in premenopausal women with advanced breast cancer and
prior progression on endocrine therapy: PALOMA-3 results.
Oncologist 2017;22:1028e38. https://doi.org/10.1634/theoncologist.
2017-0072.
[21] Verma S, Bartlett CH, Schnell P, et al. Palbociclib in combination
with fulvestrant in women with hormone receptor-positive/-
HER2-negative advanced metastatic breast cancer: detailed safety
analysis from a multicenter, randomized, placebo-controlled,
phase 3 study (PALOMA-3). Oncologist 2016;21:1165e75.
https://doi.org/10.1634/theoncologist.2016-0097.
[22] Harbeck N, Iyer S, Turner N, et al. Quality of life with palbociclib
plus fulvestrant in previously treated hormone receptor-positive,
HER2-negative metastatic breast cancer: patient-reported out-
comes from the PALOMA-3 trial. Ann Oncol 2016;27:1047e54.
https://doi.org/10.1093/annonc/mdw139.
[23] Baselga J, Campone M, Piccart M, et al. Everolimus in post-
menopausal hormone-receptor-positive advanced breast cancer.
N Engl J Med 2012;366:520e9. https://doi.org/10.1056/NEJMoa
1109653.
[24] Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus
exemestane for hormone-receptor-positive, human epidermal
growth factor receptor-2-negative advanced breast cancer: overall
survival results from BOLERO-2. Ann Oncol 2014;25:2357e62.
https://doi.org/10.1093/annonc/mdu456.
[25] Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus
exemestane in postmenopausal patients with HR(þ) breast can-
cer: BOLERO-2 final progression-free survival analysis. Adv Ther
2013;30:870e84. https://doi.org/10.1007/s12325-013-0060-1.
[26] Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain
mutations in hormone-resistant breast cancer. Nat Genet 2013;45:
1439e45. https://doi.org/10.1038/ng.2822.
[27] Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of
constitutively active estrogen receptor-alpha mutations in pre-
treated advanced estrogen receptor-positive breast cancer. Clin
Cancer Res 2014;20:1757e67. https://doi.org/10.1158/1078-0432.
ccr-13-2332.
[28] Gupta S, Zhang J, Jerusalem G. The association of chemotherapy
versus hormonal therapy and health outcomes among patients
with hormone receptor-positive, HER2-negative metastatic breast
cancer: experience from the patient perspective. Expert Rev
Pharmacoecon Outcomes Res 2014;14:929e40. https:
//doi.org/10.1586/14737167.2014.949243.
[29] Mamiya H, Tahara RK, Tolaney SM, Choudhry NK,
Najafzadeh M. Cost-effectiveness of palbociclib in hormone
receptor-positive advanced breast cancer. Ann Oncol 2017;28:
1825e31.
[30] Budczies J, Bockmayr M, Denkert C, et al. Classical pathology
and mutational load of breast cancer - integration of two worlds.
J Pathol Clin Res 2015;1:225e38. https://doi.org/10.1002/cjp2.25.
